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Gastric bypass and banding equally improve
insulin sensitivity and β cell function
David Bradley,1 Caterina Conte,1,2 Bettina Mittendorfer,1 J. Christopher Eagon,1 J. Esteban Varela,1
Elisa Fabbrini,1 Amalia Gastaldelli,3 Kari T. Chambers,1 Xiong Su,1 Adewole Okunade,1
Bruce W. Patterson,1 and Samuel Klein1
1Center

for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA. 2Department of Clinical Medicine,
Sapienza University of Rome, Rome, Italy. 3Institute of Clinical Physiology of the National Research Council, Pisa, Italy.

Bariatric surgery in obese patients is a highly effective method of preventing or resolving type 2 diabetes
mellitus (T2DM); however, the remission rate is not the same among different surgical procedures. We
compared the effects of 20% weight loss induced by laparoscopic adjustable gastric banding (LAGB) or
Roux-en-Y gastric bypass (RYGB) surgery on the metabolic response to a mixed meal, insulin sensitivity, and
β cell function in nondiabetic obese adults. The metabolic response to meal ingestion was markedly different after RYGB than after LAGB surgery, manifested by rapid delivery of ingested glucose into the systemic
circulation, by an increase in the dynamic insulin secretion rate, and by large, early postprandial increases
in plasma glucose, insulin, and glucagon-like peptide–1 concentrations in the RYGB group. However, the
improvement in oral glucose tolerance, insulin sensitivity, and overall β cell function after weight loss were
not different between surgical groups. Additionally, both surgical procedures resulted in a similar decrease
in adipose tissue markers of inflammation. We conclude that marked weight loss itself is primarily responsible for the therapeutic effects of RYGB and LAGB on insulin sensitivity, β cell function, and oral glucose
tolerance in nondiabetic obese adults.
Introduction
Obesity is an important cause of insulin resistance and impaired
pancreatic β cell function, which leads to the development of type 2
diabetes mellitus (T2DM) (1). Weight loss in obese people has
potent beneficial metabolic effects and can improve both multiorgan insulin sensitivity (2, 3) and β cell function (4, 5). In fact,
in most patients, marked weight loss induced by bariatric surgery
results in complete resolution of T2DM, usually defined as discontinuation of all diabetes medications in conjunction with some
evidence of normal glycemic control (fasting blood glucose concentration or glycated hemoglobin) (6). However, the remission
rate is not the same among surgical procedures. Procedures that
divert ingested nutrients from passage through the upper gastrointestinal tract, such as Roux-en-Y gastric bypass (RYGB) surgery,
have much higher remission rates than do procedures that simply
restrict the stomach, such as laparoscopic adjustable gastric banding (LAGB) surgery (6). This observation has led to the notion
that anatomical diversion of the upper gastrointestinal tract has
important therapeutic effects on glucose homeostasis that are
independent of weight loss itself. However, the interpretation of
this clinical observation is confounded by differences in weight
loss among surgical treatment groups (6).
The main purpose of this study was to test the hypothesis that
upper gastrointestinal tract diversion has weight loss–independent
therapeutic effects on the 2 major factors involved in the pathogenesis of T2DM: β cell function and insulin action. We evaluated the
metabolic response (glucose kinetics and β cell function) to a mixed
meal, using stable isotopically labeled tracer methods in conjunction with mathematical modeling, and assessed insulin sensitivity,
Conflict of interest: Samuel Klein serves on a Scientific Advisory Board for Ethicon
Endo-Surgery.
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using the hyperinsulinemic-euglycemic clamp procedure and stable
isotopically labeled tracer infusion, in nondiabetic obese subjects
both before undergoing RYGB or LAGB surgery and after surgeryinduced loss of a targeted 20% of body weight. We also evaluated the
effects of surgery-induced weight loss on cellular factors purported
to be involved in regulating metabolic function, specifically adipose
tissue inflammatory factors (gene expression of macrophage markers, chemokines, and cytokines) (7) and intramyocellular lipid intermediates (diacylglycerol [DAG] and ceramide content) (8).
Results
Body composition and basal metabolic variables
Subjects in the LAGB and RYGB groups lost 19.3% ± 1.9% and
20.1% ± 2.3% of their body weight by 22 ± 7 and 16 ± 2 weeks after
surgery, respectively (Table 1). The delay in achieving the target
weight loss in the LAGB group was primarily due to a slower rate
of weight loss in the first 6 weeks after surgery, before the first
band adjustment was performed. Weight loss caused marked
changes in body composition, but the effects on fat-free mass
(FFM), fat mass (FM), intra-abdominal adipose tissue (IAAT) volume, intrahepatic triglyceride (IHTG) content, and plasma leptin
concentration were not different between groups (Table 1). Weight
loss also caused beneficial changes in plasma markers of glucose
homeostasis (glucose, insulin, C-peptide, and adiponectin concentrations) and inflammation (C-reactive protein [CRP]), but these
outcome variables decreased equally in both groups after surgeryinduced weight loss (Table 1).
Insulin sensitivity
Values for insulin sensitivity, assessed by using the homeostasis
model assessment of insulin resistance (HOMA-IR), decreased by
more than half after weight loss in the LAGB and RYGB groups, but
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Table 1
Body composition and metabolic variables before and after LAGB and RYGB surgery–induced weight loss
LAGB
Body weight (kg)
BMI (kg/m2)
FFM (kg)
FM (kg)
FM (% body weight)
IAAT volume (cm3)
IHTG content (%)
Plasma glucose (mmol/l)
Plasma insulin (μU/ml)
Plasma C-peptide (pmol/l)
HOMA-IR score
Glucose AUC (mg/dl × 360 min × 103)
C-peptide AUC (pmol/l × 360 min × 103)
Insulin AUC (μU/ml × 360 min × 103)
Leptin (ng/ml)
Adiponectin (μg/ml)
C-reactive protein (ng/l)

RYGB

Before

After

Before

After

128.7 ± 29.6
46.5 ± 8.8
62.5 ± 13.0
67.1 ± 22.5
51.2 ± 5.7
1,587 ± 440
12.8 ± 9.8
5.3 ± 0.4
12.6 ± 4.1
1,130 ± 262
5.8 ± 1.9
40.3 ± 2.3
764 ± 108
11.6 ± 4.8
62.5 ± 25.6
8.2 ± 3.3
12.4 ± 9.8

104.1 ± 24.5A
37.6 ± 7.3A
56.8 ± 11.7A
49.8 ± 20.1A
45.7 ± 7.2A
1,056 ± 332A
4.6 ± 4.3A
4.7 ± 0.3A
6.1 ± 1.9A
726 ± 205A
2.3 ± 0.8A
38.0 ± 2.3A
608 ± 126A
6.5 ± 2.4A
30.9 ± 20.4A
11.3 ± 5.1A
7.2 ± 5.7A

132.0 ± 28.4
45.6 ± 6.7
62.6 ± 13.5
68.2 ± 17.1
51.9 ± 4.1
1,912 ± 917
10.5 ± 7.6
5.0 ± 0.5
14.5 ± 7.5
1,170 ± 525
5.8 ± 2.3
40.3 ± 2.7
802 ± 221
12.9 ± 5.4
64.3 ± 24.6
7.2 ± 3.2
11.4 ± 14.3

105.5 ± 23.1A
36.4 ± 5.0A
56.2 ± 11.6A
49.4 ± 12.8A
46.5 ± 4.0A
1,060 ± 435A
3.8 ± 4.1A
4.6 ± 0.4A
5.7 ± 2.6A
699 ± 205A
1.8 ± 0.9A
39.3 ± 1.3A
631 ± 117A
8.5 ± 2.4A
23.5 ± 13.5A
10.3 ± 5.1A
5.2 ± 4.8A

Values are means ± SD. AP < 0.05 vs. before surgery. No significant effect of group or time-group interaction was observed.

there was no significant difference between groups (Table 1). Insulinmediated stimulation of glucose disposal above basal values nearly
doubled after weight loss in both the LAGB and RYGB groups, but
there was no significant difference between groups (Figure 1).
β Cell function
Total insulin secretion rate (ISR) in response to the mixed meal
decreased after both LAGB and RYGB surgery-induced weight loss,
and the decrease was similar in both groups (Figure 2A). Dynamic
ISR increased after RYGB-induced, but not LAGB-induced, weight
loss (Figure 2B). Static ISR decreased to a similar extent after both
LAGB (from 41.3 ± 4.6 × 103 to 31.5 ± 5.1 × 103 nmol/l per 360
min) and RYGB (from 45.1 ± 13.4 × 103 to 29.2 ± 5.0 × 103 nmol/l
per 360 min) surgery-induced weight loss. Total β cell sensitivity
(Φtotal) decreased after surgery-induced weight loss to the same
extent in both groups (Figure 2C). The disposition index (DI)
nearly doubled after LAGB- and RYGB-induced weight loss, but
there was no difference between groups (Figure 2D).
Metabolic response to a mixed meal
Plasma hormone concentrations. Postprandial AUCs for plasma insulin and C-peptide concentrations decreased to a similar extent in
both groups after surgery-induced weight loss (Table 1). However,
RYGB surgery altered the shape of the concentration curves, manifested by a much higher peak in the early rise of plasma insulin
and C-peptide after surgery than before (Figure 3). In addition,
RYGB surgery, but not LAGB surgery, caused a marked increase in
postprandial plasma active glucagon-like peptide–1 (GLP-1) concentration (Figure 3). Neither LAGB nor RYGB surgery affected
plasma glucagon concentrations (Figure 3).
Glucose kinetics. The AUC for plasma glucose after ingesting the
mixed meal decreased to a similar extent in both groups after surgery-induced weight loss (Table 1). However, in contrast to LAGB,
RYGB resulted in a much higher peak in the early rise of plasma glucose concentration, because of a marked increase in the early rate
4668

of appearance (Ra) of ingested glucose into the systemic circulation
(Figure 4). Most of the ingested glucose appeared in the circulation
within 120 minutes of initiating meal consumption; the percentage
of total meal-derived glucose that appeared in the circulation within 120 minutes of initiating meal ingestion was 75% ± 14% before
and 73% ± 13% after surgery in the LAGB group, but increased from
70% ± 19% before to 92% ± 2% after surgery in the RYGB group
(P = 0.01). Before surgery, meal ingestion caused a prompt and nearly complete suppression of endogenous glucose production (EGP),
which did not return to baseline even 5.5 hours after completing meal consumption (Figure 4). Therefore, EGP accounted for
less than 10%, whereas ingested glucose accounted for more than
90%, of glucose in plasma at the end of meal ingestion (Figure 4).
The suppression of EGP in response to meal ingestion was not
different before and after surgery in the LAGB group. In contrast,
RYGB surgery resulted in a more rapid and almost complete suppression of EGP, which rapidly returned to baseline levels.
Cellular factors involved in metabolic regulation
Subcutaneous adipose tissue inflammation. Weight loss caused a marked
decrease in adipose tissue gene expression (as assessed by mRNA
content) of proinflammatory macrophage cell surface markers
(EMR1 and CD11B), chemokines (CCL2), and proinflammatory
cytokines (CSF3, IL6, TNFA, and LEP), but increased the expression of the antiinflammatory cytokine IL10 (Figure 5). However,
the changes in these pro- and antiinflammatory markers were not
different between surgical groups.
Skeletal muscle lipid metabolites. Weight loss did not result in a decrease
in either intramyocellular total DAG or ceramide content (Figure 6).
Discussion
In the present study, we evaluated whether bariatric surgery that
bypasses the upper gastrointestinal tract has important weight
loss–independent effects on plasma glucose homeostasis in nondiabetic obese subjects after they have experienced considerable sur-
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Figure 1
Glucose disposal during basal conditions and insulin infusion before and
after 20% weight loss induced by LAGB or RYGB surgery. *P < 0.001 vs.
before surgery; †P < 0.001 vs. basal. Values are means ± SEM.

function that occurs as obese people progress from normal glucose homeostasis to T2DM (14) can be prevented by weight loss
induced by either LAGB or RYGB surgery.
The pattern of the metabolic response to mixed meal ingestion
was very different after RYGB than after LAGB surgery-induced
weight loss. Although total postprandial ISR and plasma glucose
concentration AUCs were the same after both surgical procedures,
the dynamic ISR, which represents the insulin response to increasing plasma glucose concentration (predominantly during the first
60 minutes after initiating meal ingestion and usually accounting
for up to 10% of total ISR), increased markedly after RYGB surgery, but did not change after LAGB surgery. The increase in the
dynamic ISR was likely a direct consequence of the rapid rate of
glucose absorption, presumably due to rapid emptying of the meal
into the small intestine (15), and subsequent rapid rise in plasma
glucose concentration, in conjunction with an increase in the insulin response to plasma glucose because of an increase in plasma
GLP-1 (16, 17). However, the increase in early meal-induced ISR
after RYGB surgery did not prevent a marked increase in the early
peak in plasma glucose concentration. The clinical implications
of this altered metabolic response to a meal are not clear, but it
does not necessarily demonstrate a beneficial effect, because a high
peak postprandial glucose concentration is associated with insulin
resistance and cardiovascular disease (18–21).
The delivery of ingested glucose into the systemic circulation
was responsible for the increase in postprandial plasma glucose
concentration, because hepatic glucose production was almost
completely suppressed by the meal-induced increase in circulating insulin. This synergy between glucose absorption and EGP is
critical to prevent excessive postprandial plasma glucose concentrations. Subjects who had RYGB surgery displayed a more rapid
return toward baseline EGP rate than those who had LAGB, thereby preventing a continued decline in plasma glucose in the former
group. The increase in EGP in the RYGB group was likely caused
by a rapid decline in plasma insulin. These results underscore the
importance of hepatic function in preventing postprandial hypoglycemia in patients who have had RYGB surgery.

gery-induced weight loss. Our data demonstrated that both insulin sensitivity, assessed as insulin-mediated glucose disposal, and
β cell function, assessed as the DI (β cell response to a mixed meal
in relationship to insulin sensitivity), improved markedly after
20% weight loss, but there were no differences between surgical
groups. However, RYGB surgery altered the metabolic response to
ingesting a mixed meal, characterized by rapid delivery of ingested
glucose into the systemic circulation, which was responsible for a
large early increase in plasma glucose concentration and insulin
secretion. In contrast, the rate of delivery of ingested glucose into
the circulation and the shapes of the plasma glucose and insulin response curves to a mixed meal did not change after LAGBinduced weight loss. These results demonstrated that even though
upper gastrointestinal tract diversion caused profound changes in
certain aspects of the metabolic response to a meal, weight loss
itself was primarily responsible for the long-term therapeutic
effects of RYGB and LAGB on β cell function, insulin sensitivity,
and oral glucose tolerance in nondiabetic obese adults.
Insulin-resistant glucose metabolism in skeletal muscle, one
of the most common metabolic abnormalities associated with
obesity, is an important risk factor for developing the metabolic
syndrome, T2DM, and coronary heart disease (9). Data from previous studies have found that moderate weight loss
(5%–10%), induced by RYGB surgery or diet therapy
alone, does not affect insulin-mediated glucose disposal (10–13). Therefore, the results from our study,
in conjunction with the data obtained from these previous studies, indicate that marked weight loss (20%)
is needed to improve skeletal muscle insulin sensitivity
in extremely obese people. Moreover, the improvement
in insulin sensitivity was the same in both the RYGB
and LAGB groups, which demonstrated that RYGB
did not have weight loss–independent effects on skeletal muscle insulin action.
Weight loss resulted in a 25% decrease in total mealinduced insulin secretion in both LAGB and RYGB
groups. This decrease was expected, because less insulin is needed to respond to an oral glucose challenge
when insulin sensitivity has increased. However, the
decline in insulin secretion was much less than the
nearly 2-fold increase in insulin sensitivity. Accordingly, β cell function, assessed as total meal-induced Figure 2
insulin secretion in relationship to insulin sensitivity Total ISR (A), dynamic ISR (B), Φtotal (C), and DI (D) before and after 20% weight
(i.e., DI), increased approximately 75% in both surgical loss induced by LAGB or RYGB surgery. *P < 0.001 vs. before surgery. Values
groups. These data suggest the deterioration in β cell are means ± SEM.
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Figure 3
Plasma hormone concentrations after ingestion of a mixed meal (consumed over 30
minutes) before and after 20% weight loss
induced by LAGB or RYGB surgery. Weight
loss–induced changes in plasma insulin,
C-peptide, and active GLP-1 concentrations
were significantly different between LAGB
and RYGB groups (P < 0.0001 for all). There
was no significant effect of weight loss on
plasma glucagon concentrations. Values are
means ± SEM.

Our data demonstrated that weight loss, induced by either
LAGB or RYGB surgery, had the same beneficial effects on several
factors that have been previously proposed to regulate metabolic
function in obese people, namely body composition, circulating
adiponectin, and markers of inflammation in both plasma and
adipose tissue (22). Surgery-induced weight loss decreased body
FM, IAAT volume, and IHTG content; increased plasma adiponectin concentration; decreased plasma CRP concentration; and had
beneficial effects on multiple pathways of adipose tissue inflammation, manifested by decreased gene expression of proinflammatory macrophages (EMR1 and CD11B), chemokines (CCL2), and
cytokines (CSF3, IL6, TNFA, and LEP) and increased gene expression of the antiinflammatory cytokine IL10. However, no differences in any of these outcome measures were detected between surgical groups, which suggests that weight loss itself, rather than the
type of surgery, is responsible for the beneficial effects. In contrast,
we found that weight loss did not affect intramyocellular DAG or
ceramide content, which have previously been shown to impair
muscle insulin signaling in rodent models (23, 24). Therefore,
our results suggest these lipid intermediates were not important
4670

mediators of the improvement in skeletal
muscle insulin sensitivity observed in our
subjects. These data underscore the need
for additional studies to evaluate the
importance of intramyocelluar DAG and
ceramide in the pathogenesis of skeletal
muscle insulin resistance in obese people.
All study subjects were insulin resistant,
based on a HOMA-IR value greater than
2.5, but none had T2DM. Studying subjects without T2DM allowed us to avoid
the confounding effects of differences in
baseline glycemic control, glucose toxicity, and changes in diabetes medications
on our metabolic outcome measures.
Accordingly, it cannot be assumed that
our results apply to the diabetic population, and additional studies are needed
in participants with T2DM. Nonetheless,
our study population does not diminish
the relevance of our findings, because
most patients who undergo bariatric surgery (∼80%) do not have T2DM (25).
In conclusion, the results from our
study provide insights into the physiological effects of marked RYGB- and
LAGB-induced weight loss on the metabolic response to a meal, on β cell function, and on insulin sensitivity in weight loss–matched groups of obese people who do not
have T2DM. Our data demonstrated potent but similar beneficial
effects of marked weight loss, induced by either LAGB or RYGB,
on both β cell function and insulin sensitivity in obese people. In
contrast, specific aspects of the metabolic response to a mixed
meal were profoundly different between surgical procedures,
because of rapid absorption of ingested glucose after RYGB that
resulted in a marked transient increase in plasma glucose, insulin,
and GLP-1 concentrations. However, it is not clear that the alterations in hormone secretion after RYGB have important therapeutic effects on glycemic control, because they did not prevent a large
early increase in plasma glucose concentration or result in a greater reduction in postprandial glucose concentration AUC in this
group. Therefore, our data do not support the notion of clinically
meaningful weight loss–independent effects of RYGB surgery on
β cell function and insulin sensitivity in nondiabetic obese subjects after they have experienced considerable weight loss. Additional studies are needed to determine whether these findings also
apply to obese people with T2DM.
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Figure 4
Plasma glucose concentration, ingested
glucose Ra into the systemic circulation, EGP rate, and EGP as percentage
of total glucose Ra into the systemic circulation after ingestion of a mixed meal
(consumed over 30 minutes) before and
after 20% weight loss induced by LAGB
or RYGB surgery. Weight loss–induced
changes in all parameters shown were
significantly different between LAGB and
RYGB groups (P < 0.0001). Values are
means ± SEM.

Methods
Selection and description of participants
20 consecutive, eligible patients who were scheduled to undergo RYGB (n = 10;
2 men, 8 women; 43 ± 7 years old) or LAGB (n = 10; 1 man, 9 women; 47 ± 14
years old) procedures at Barnes-Jewish Hospital (St. Louis, Missouri, USA)
participated in this study, which was approved by the Washington University Institutional Review Board. All participants provided written informed
consent and completed a comprehensive medical evaluation. Potential participants who smoked cigarettes, had previous malabsorptive or restrictive
intestinal surgery, had a history of inflammatory intestinal disease, had evidence of severe organ dysfunction, had uncontrolled hypertension, or had
a serum triglyceride concentration of 400 mg/dl or higher were excluded.
Potential participants who had diabetes were excluded to avoid the confounding effects of differences in baseline glycemic control, glucose toxicity,
and postsurgical changes in diabetes medications on our outcome measures.

Study design and experimental procedures
Each subject completed body composition analyses, a hyperinsulinemiceuglycemic clamp procedure, and a mixed-meal metabolic study before
bariatric surgery and after 20% surgery-induced weight loss.
Body composition assessments. Body FM and FFM, IAAT volume, and
IHTG content were determined using dual-energy X-ray absorptiometry, magnetic resonance imaging, and magnetic resonance spectroscopy, respectively (26, 27).

Hyperinsulinemic-euglycemic clamp procedure. Subjects were admitted to the
Washington University School of Medicine Clinical Research Unit (CRU)
and consumed a standard evening meal (12 kcal/kg FFM; 50% of calories as
carbohydrate, 30% as fat, 20% as protein). The following morning, a catheter was inserted into a forearm vein for infusion, and a second catheter
was inserted into a radial artery to obtain blood samples. At 6:00 am, a
primed, continuous infusion of [6,6-2H2]glucose (priming dose, 22 μmol/
kg; infusion rate, 0.22 μmol/kg/min) was started and maintained until the
end of the study. At 9:30 am, insulin was infused at a rate of 50 mU × m2
body surface area × min–1 for 4 hours. Euglycemia (plasma glucose ∼100
mg/dl) was maintained by infusion of 20% dextrose enriched to 2.5% with
[6,6-2H2]glucose. Blood samples were obtained immediately before starting
the tracer infusion and during the final 30 minutes of the basal period and
the clamp procedure to determine plasma substrate and insulin concentrations as well as glucose tracer/tracee ratios (TTRs).
Subcutaneous abdominal adipose tissue and vastus lateralis muscle tissue samples were obtained by percutaneous biopsy 60 minutes after starting the glucose tracer infusion during basal conditions. Biopsy sites were
cleaned and draped. After anesthetizing the skin and underlying tissues with
lidocaine, adipose tissue was aspirated from the periumbilical area using a
14-gauge needle, and skeletal muscle was obtained using Tilley-Henkel forceps (Sontec Instruments). Tissue samples were immediately rinsed with
ice-cold saline and frozen in liquid nitrogen before being stored at –80°C.
Mixed meal metabolic study. Subjects were admitted to the CRU and
consumed a standard evening meal. The following morning, a catheter
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Figure 5
Adipose tissue gene expression of proinflammatory
macrophage cell surface markers (EMR1 and CD11B),
chemokines (CCL2), cytokines (CSF3, IL6, TNFA, and
LEP), and the antiinflammatory cytokine IL10 before and
after 20% weight loss induced by LAGB (n = 8) or RYGB
(n = 8) surgery. *P < 0.05 vs. before surgery. Values are
means ± SEM.

was inserted into a forearm vein for infusion, and a second catheter was
inserted into a radial artery to obtain blood samples. A primed, continuous infusion of [6,6-2H2]glucose (priming dose, 22 μmol/kg; infusion rate,
0.22 μmol/kg/min) was started and continued until the end of the study.
After 3.5 hours of tracer infusion, subjects ingested a liquid meal (containing 46 g glucose mixed with 0.9 g [U-13C]glucose, 9 g fat, and 9 g protein),
which was provided in 7 equally divided aliquots given every 5 minutes
over a 30-minute period. Blood samples were obtained immediately before
starting the glucose tracer infusion, every 10 minutes for 30 minutes just
before starting the meal ingestion, and then every 15 minutes for the first
hour and every 20 minutes for the subsequent 5 hours after starting the
meal, to determine plasma substrate and hormone concentrations as well
as glucose TTRs.

Surgical procedures
Bariatric surgeries were performed using standard laparoscopic approaches.
The RYGB procedure involved creating a small (∼30 ml) proximal gastric
pouch and a stapled gastrojejunostomy. A 100-cm Roux limb was constructed by transecting the jejunum 30 cm distal to the ligament of Treitz
and performing a stapled jejunojejunostomy at this site (28). The standard
pars flaccid technique was used for LAGB (Lap-Band; Allergan; ref. 29).

Weight management after surgery
Subjects participated in a supervised dietary weight loss
program to help subjects in both groups consume a similar energy-deficit diet and achieve a 20% weight loss within 4–6 months after surgery. All subjects were instructed
to consume a clear liquid diet (400–600 kcal/d) for the
first 2 days after surgery, a full liquid diet (400–600
kcal/d) on postoperative day 3, a pureed diet (2–3 oz/
meal providing 700–800 kcal/d) on days 4–7, and a soft
diet (3–4 oz/meal providing 800–1,000 kcal/d) on days
8–29, followed by a regular-food diet containing 1,000–
1,200 kcal/d and 1.0 g protein/kg body weight/d. After
subjects achieved a 20% weight loss, a balanced weight
maintenance diet was prescribed, and subjects main4672

tained a stable body weight (<2% change) for at least 2 weeks before repeat
studies were performed.

Analyses of blood samples
Plasma glucose concentration was determined using an automated glucose analyzer (YSI 2300 STAT plus; Yellow Spring Instrument Co.). Plasma
C-peptide, insulin, glucagon, active GLP-1, leptin, adiponectin, and CRP
concentrations were measured using enzyme-linked immunosorbent
assays (Millipore). Plasma glucose TTRs were determined by using gas
chromatography–mass spectrometry (30).

Analyses of adipose tissue samples
Isolation of mRNA and quantitative PCR. Frozen adipose tissue samples were
homogenized in RNAzol Bee (Tel-Test Inc.), and RNA was isolated according to the manufacturer’s protocol. Gene expression was determined using
quantitative real-time PCR. cDNA was synthesized by using SuperScript
VILO (Life Technologies), and cDNA samples were amplified by using
SybrGreen reagent and the ABI 7500 thermal cycler (Life Technologies).
The expression of each gene (EMR1, CD11B, CCL2, CSF3, IL6, TNFA, IL10,
and LEP) was determined by correcting the threshold crossing (Ct) of each
sample to the housekeeping control gene, acidic ribosomal phosphoprotein P0 (36B4), calculated as 2–ΔCt. The following primer sequences were
used: EMR1, GGAAGGGCACATAAGACCCAG and GGGCACAAGG-

Figure 6
Skeletal muscle DAG and ceramide content before and after 20% weight loss induced
by LAGB (n = 10) or RYGB (n = 7) surgery. Values are means ± SEM.
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TACTGTCTCTA; CD11B, CAGCCTTGACCTTATGTCATGG and CCTGTGCTGTAGTCGCACT; CCL2, ATAGCAGCCACCTTCATTCC and
GCTTCTTTGGGACACTTGCT; CSF3, GCGGCTTGAGCCAACTCCATA
and GAACGCGGTACGACACCTC; IL6, CCTGAACCTTCCAAAGATGG
and TGGCTTGTTCCTCACTACTCTC; TNFA, GGAAAGGACACCATGAGCA and CAGAGGGCTCATTAGAGAGAGG; IL10, TCAAGGCGCATGTGAA and GATGTCAAACTCACTC; LEP, GTGGCTTTGGCCCTATCTT
and GCATACTGGTGAGGATCTGTTG; 36B4, GTGATGTGCAGCTGATCAAGACT and GATGACCAGCCCAAAGGAGA.

Analyses of skeletal muscle lipid metabolites
Intramyocellular DAG and ceramide concentrations were determined using
mass spectrometry (31). Muscle tissue samples were weighed and lipids were
extracted as we previously described (32). About 10% of the lipid extract
was used to evaluate ceramide content. Quantitation of ceramide molecular
species was performed by using a Thermo triple quadrupole (TSQ) Vantage mass spectrometer and electrospray ionization (ESI) (33). Neutral lipids were extracted from the rest of the lipid extract by hexane and the free
hydroxyl group in DAG was protected with 2,4-diflourophenyl isocyanate
to quantitate DAG molecular species using an Agilent 1100 LC system connected to an Agilent 6460 TSQ mass spectrometer operated in ESI and positive ion mode (34). The LC system allows separation of DAG species from
other neutral lipids and resolution of 1,2-sn-DAG and 1,3-sn-DAG species.
Total DAG and ceramide contents were calculated by summation of the
individual 1,2-sn-DAG (C22:0, C23:0, C24:0, C25:0, C26:0, C27:0, C28:0,
C29:0, C30:1, C30:0, C31:0, C30:0, C31:0, C32:2, C32:1, C32:0, C33:1, C33:0,
C34:3, C34:2, C34:1, C34:0, C35:1, C35:0, C36:4, C36:3, C36:2, C36:1, C36:0,
C38:5, C38:4, C38:3, C38:2, C40:5) and 1,3-sn-DAG (C22:0, C24:0, C26:0,
C28:0, C30:0, C32:1, C32:0, C34:2, C34:1, C34:0, C36:3, C36:2, C36:1, C36:0)
species and the individual ceramide (C16:0, C18:1, C18:0, C19:0, C20:0,
C22:0, C23:0, C24:2, C24:1, C24:0, C24:1OH, C24:0OH) species.

Calculations
Insulin sensitivity. HOMA-IR was used to provide an index of whole-body
insulin resistance (35). Glucose Ra into plasma was calculated by dividing
the tracer infusion rate by the average plasma glucose TTR during the last
30 minutes of the basal and insulin infusion periods (36). Glucose disposal rate was equal to endogenous glucose Ra plus the rate of exogenously
infused dextrose and glucose tracer. Insulin-stimulated glucose uptake was
used as an index of skeletal muscle insulin sensitivity.
β Cell function. Minimal model analysis was used to calculate Φtotal, an
overall index of postprandial insulin secretion in response to plasma glucose, using plasma C-peptide as a function of glucose concentration (37).
The minimal model can also resolve the total ISR into 2 components representing the release of insulin from 2 distinct pools of insulin secretory
granules within the β cell: a dynamic component that represents the rapid
release of a “readily releasable pool,” which usually accounts for less than
10% of total insulin secretory granules, and a static component that represents the slower release of a “reserve pool” of insulin secretory granules
(38). The DI, which provides an assessment of insulin secretion in relationship to insulin sensitivity (39), was calculated as the product of Φtotal and
the change in glucose Rd per kg FFM per change in insulin concentration
during the hyperinsulinemic-euglycemic clamp procedure.
Metabolic response to the mixed meal. Plasma glucose, insulin, and C-peptide concentration AUCs for 6 hours after initiating meal consumption
1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787–835, ix.
2. Niskanen L, Uusitupa M, Sarlund H, Siitonen O,
Paljarvi L, Laakso M. The effects of weight loss on
insulin sensitivity, skeletal muscle composition and

were calculated using the trapezoid method (40). Total glucose Ra into
the systemic circulation during the meal was calculated using Steele’s
equation for non–steady-state conditions (36). Glucose Ra into the systemic circulation from ingested glucose and from EGP were calculated
as previously described (41).

Statistics
Data were examined for normality according to the Shapiro-Wilks criteria, and non–normally distributed data sets were log-transformed before
statistical analyses were performed. A 2-way repeated measures analysis of
variance with Tukey’s post-hoc procedure was used to compare the effects
of RYGB and LAGB surgery on study outcome measures (except for postprandial metabolic outcomes) in the 2 groups. For postprandial metabolic
outcomes, mixed-model repeated-measures analysis of variance was used
to evaluate differences in weight loss–induced changes between LAGB and
RYGB groups. A P value of 0.05 or less was considered statistically significant. All data are presented as means ± SD unless otherwise indicated.
Based on the interindividual variability of glucose rate of disappearance
(Rd) during a hyperinsulinemic-euglycemic clamp procedure in a large
cohort of nondiabetic obese subjects we previously studied (42), we estimated that 10 subjects in each group (RYGB and LAGB) would be needed
to detect a 40% difference in insulin-stimulated glucose Rd between the
RYGB and the LAGB group with a β value of 0.20 (i.e., 80% power) and an
α value of 0.05. This proposed difference between groups is a conservative
estimate based on the results from the only 2 previous studies comparing
the effect of gastric restriction versus RYGB procedures on insulin sensitivity using the hyperinsulinemic clamp procedure (43, 44). In both studies, insulin-stimulated glucose disposal was more than 200% greater after
RYGB than after restrictive surgical procedures.

Study approval
This study was approved by the Human Research Protection Office at
Washington University School of Medicine. All study subjects provided
written informed consent before screening and participation in the study.

Acknowledgments
The authors thank Courtney Tiemann for help with subject
recruitment and dietary counseling; Hua Cheng, Freida Custodio,
Jennifer Shew, Ioana Gruchevska, and Terri Pietka for technical
assistance; Faidon Magkos and Kenneth Schechtman for statistical support; the staff of the Clinical Research Unit for their help
in performing the studies; and the study subjects for their participation. This study was supported by NIH grants DK 37948,
DK 56341 (Nutrition Obesity Research Center), UL1 RR024992
(Clinical and Translational Science Award), and RR-00954 (Biomedical Mass Spectrometry Resource); by a grant from Ethicon
Endo-Surgery; and by the Atkins Foundation Philanthropic Trust.
Received for publication May 21, 2012, and accepted in revised
form September 6, 2012.
Address correspondence to: Samuel Klein, Center for Human Nutrition, Washington University School of Medicine, 660 South Euclid
Avenue, Campus Box 8031, St. Louis, Missouri 63110, USA. Phone:
314.362.8708; Fax: 314.362.8230; E-mail: sklein@dom.wustl.edu.

capillary density in obese non-diabetic subjects. Int J
Obes Relat Metab Disord. 1996;20(2):154–160.
3. Gregor MF, et al. Endoplasmic reticulum stress is
reduced in tissues of obese subjects after weight
loss. Diabetes. 2009;58(3):693–700.

4. Villareal DT, Banks MR, Patterson BW, Polonsky
KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity (Silver Spring). 2008;16(6):1349–1354.
5. Guldstrand M, Ahren B, Adamson U. Improved

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 12   December 2012

4673

Downloaded on October 19, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/64895

research article
beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab. 2003;284(3):E557–E565.
6. Buchwald H, et al. Weight and type 2 diabetes after
bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5.
7. Chawla A, Nguyen KD, Goh YP. Macrophagemediated inflammation in metabolic disease. Nat
Rev Immunol. 2011;11(11):738–749.
8. Eckardt K, Taube A, Eckel J. Obesity-associated
insulin resistance in skeletal muscle: role of lipid
accumulation and physical inactivity. Rev Endocr
Metab Disord. 2011;12(3):163–172.
9. Jornayvaz FR, Samuel VT, Shulman GI. The role
of muscle insulin resistance in the pathogenesis of
atherogenic dyslipidemia and nonalcoholic fatty
liver disease associated with the metabolic syndrome. Annu Rev Nutr. 2010;30:273–290.
10. Lima MM, et al. Acute effect of roux-en-y gastric
bypass on whole-body insulin sensitivity: a study
with the euglycemic-hyperinsulinemic clamp. J Clin
Endocrinol Metab. 2010;95(8):3871–3875.
11. Campos GM, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed
only after substantial weight loss has occurred and
correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14(1):15–23.
12. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler
RE, Shulman GI. Reversal of nonalcoholic hepatic
steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with
type 2 diabetes. Diabetes. 2005;54(3):603–608.
13. Sato F, et al. Effects of diet-induced moderate weight
reduction on intrahepatic and intramyocellular
triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab. 2007;92(8):3326–3329.
14. Elder DA, Prigeon RL, Wadwa RP, Dolan LM,
D’Alessio DA. Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and
nondiabetic adolescents and young adults. J Clin
Endocrinol Metab. 2006;91(1):185–191.
15. Wang G, et al. Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass
surgery (GBP). Obes Surg. 2012;22(8):1263–1267.
16. Bose M, et al. Weight loss and incretin responsiveness improve glucose control independently after
gastric bypass surgery. J Diabetes. 2012;2(1):47–55.
17. Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass
surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans.
Diabetes. 2011;60(9):2308–2314.

4674

18. Temelkova-Kurktschiev TS, et al. Postchallenge plasma glucose and glycemic spikes are more strongly
associated with atherosclerosis than fasting glucose
or HbA1c level. Diabetes Care. 2000;23(12):1830–1834.
19. Anan F, et al. Postchallenge plasma glucose and glycemic spikes are associated with pulse pressure in
patients with impaired glucose tolerance and essential
hypertension. Hypertens Res. 2008;31(8):1565–1571.
20. Hu Y, Liu W, Huang R, Zhang X. Postchallenge
plasma glucose excursions, carotid intima-media
thickness, and risk factors for atherosclerosis in
Chinese population with type 2 diabetes. Atherosclerosis. 2010;210(1):302–306.
21. Esposito K, et al. Post-meal glucose peaks at home
associate with carotid intima-media thickness
in type 2 diabetes. J Clin Endocrinol Metab. 2008;
93(4):1345–1350.
22. Samuel VT, Shulman GI. Mechanisms for insulin
resistance: common threads and missing links. Cell.
2012;148(5):852–871.
23. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin
Invest. 2011;121(11):4222–4230.
24. Samuel VT, Petersen KF, Shulman GI. Lipidinduced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733):2267–2277.
25. Schauer PR, et al. Effect of laparoscopic Roux-en Y
gastric bypass on type 2 diabetes mellitus. Ann Surg.
2003;238(4):467–484.
26. Frimel TN, Deivanayagam S, Bashir A, O’Connor
R, Klein S. Assessment of intrahepatic triglyceride
content using magnetic resonance spectroscopy.
J Cardiometab Syndr. 2007;2(2):136–138.
27. Vitola BE, et al. Weight loss reduces liver fat and
improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring).
2009;17(9):1744–1748.
28. Varela JE. Bariatric surgery: a cure for diabetes? Curr
Opin Clin Nutr Metab Care. 2011;14(4):396–401.
29. Varela JE, Hinojosa MW, Nguyen NT. Perioperative
outcomes of bariatric surgery in adolescents compared with adults at academic medical centers. Surg
Obes Relat Dis. 2007;3(5):537–540.
30. Fabbrini E, et al. Intrahepatic fat, not visceral fat,
is linked with metabolic complications of obesity.
Proc Natl Acad Sci U S A. 2009;106(36):15430–15435.
31. Magkos F, et al. Intrahepatic diacylglycerol content
is associated with hepatic insulin resistance in obese
subjects. Gastroenterology. 2012;142(7):1444–1446.e2.
32. Li YL, Su X, Stahl PD, Gross ML. Quantification
of diacylglycerol molecular species in biological

samples by electrospray ionization mass spectrometry after one-step derivatization. Anal Chem.
2007;79(4):1569–1574.
33. Han X. Characterization and direct quantitation
of ceramide molecular species from lipid extracts
of biological samples by electrospray ionization
tandem mass spectrometry. Anal Biochem. 2002;
302(2):199–212.
34. Leiker TJ, Barkley RM, Murphy RC. Analysis of diacylglycerol molecular species in cellular lipid extracts
by normal-phase LC-electrospray mass spectrometry. Int J Mass Spectrom. 2011;305(2–3):103–109.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA,
Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations
in man. Diabetologia. 1985;28(7):412–419.
36. Steele R. Influences of glucose loading and of
injected insulin on hepatic glucose output. Ann N Y
Acad Sci. 1959;82:420–430.
37. Breda E, Toffolo G, Polonsky KS, Cobelli C. Insulin release in impaired glucose tolerance: oral
minimal model predicts normal sensitivity to glucose but defective response times. Diabetes. 2002;
51(suppl 1):S227–S233.
38. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity
and diabetes. J Clin Invest. 2011;121(6):2118–2125.
39. Bergman RN, Ader M, Huecking K, Van Citters G.
Accurate assessment of β-cell function: the hyperbolic correction. Diabetes. 2002;51(suppl 1):S212–S220.
40. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other
metabolic curves. Diabetes Care. 1994;17(2):152–154.
41. Gastaldelli A, et al. Effect of pioglitazone on the
metabolic and hormonal response to a mixed
meal in type II diabetes. Clin Pharmacol Ther. 2007;
81(2):205–212.
42. Conte C, Fabbrini E, Kars M, Mittendorfer B,
Patterson BW, Klein S. Multiorgan insulin sensitivity in lean and obese subjects. Diabetes Care.
2012;35(6):1316–1321.
43. Kashyap SR, et al. Acute effects of gastric bypass
versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese
patients with type 2 diabetes. Int J Obes (Lond).
2010;34(3):462–471.
44. Abbatini F, et al. Long-term effects of laparoscopic
sleeve gastrectomy, gastric bypass, and adjustable
gastric banding on type 2 diabetes. Surg Endosc.
2010;24(5):1005–1010.

The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 12   December 2012

